Essex Bio-Technology Sets 2026 AGM, Proposes Dividend and Share Issue Mandate

Essex Bio-Technology ( (HK:1061) ) has provided an announcement.

Essex Bio-Technology has convened its annual general meeting for 26 May 2026 in Hong Kong, where shareholders will review the audited consolidated financial statements for the year ended 31 December 2025 and the accompanying directors’ and auditors’ reports. The agenda also includes separate resolutions to re-elect three retiring directors, authorize the board to set directors’ remuneration and re-appoint BDO Limited as the company’s auditor.

Shareholders will vote on a proposed final dividend of HK$0.07 per share for 2025, underscoring management’s willingness to return cash to investors while maintaining balance sheet flexibility. The meeting will further seek approval for a general mandate allowing the board to allot, issue or deal with additional shares up to 20% of the existing issued share capital, excluding treasury shares, which would give Essex Bio-Technology extra capacity to raise equity for future expansion or strategic initiatives without calling a separate shareholder meeting.

The most recent analyst rating on (HK:1061) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Essex Bio-Technology stock, see the HK:1061 Stock Forecast page.

More about Essex Bio-Technology

Essex Bio-Technology Limited is a Hong Kong-listed company incorporated in the Cayman Islands and traded under stock code 1061. It operates in the biopharmaceutical and healthcare sector, focusing on the development, manufacturing and commercialization of therapeutic products for markets in Hong Kong, mainland China and potentially broader Asian regions.

Average Trading Volume: 490,754

Technical Sentiment Signal: Hold

Current Market Cap: HK$2.05B

For detailed information about 1061 stock, go to TipRanks’ Stock Analysis page.